DrugBiological
Tafasitamab clinical trials
Also written MOR00208, MOR208, Monjuvi and Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer.
- studies test it
- 43
- open now
- 19
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the tafasitamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 2 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 34
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 26
Incyte Corporation (7) · MorphoSys AG (4) · University of Washington (3) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (2) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · David Bond, MD (1)
Often tested with
Tested in the same studies.
Lenalidomide (20) · Rituximab (10) · Acalabrutinib (5) · Venetoclax (3) · Zanubrutinib (2) · Dexamethasone (2) · Glofitamab (2) · Polatuzumab vedotin (2)
Studies
Open first, then newest update. How each study uses tafasitamab is read from its arms, and is right about nine times in ten.
Testing it · 43
- Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingPhase 2University of WashingtonNCT07731789Written as Tafasitamab
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab, tafasitamab and lenalidomide
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingPhase 1/2Alvaro Alencar, MDNCT06029309Written as Tafasitamab
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT05615636Written as Tafasitamab
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingPhase 1Paolo Caimi, MDNCT07225439Written as Tafasitamab
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Tafasitamab
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06792825Written as Tafasitamab
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingPhase 1/2James RubensteinNCT05351593Written as Tafasitamab
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07585747Written as Tafasitamab
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingPhase 2City of Hope Medical CenterNCT07582159Written as Tafasitamab
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderRecruitingPhase 2Timothy VoorheesNCT05786040Written as Tafasitamab
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06760156Written as Tafasitamab
- Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage LeukemiaRecruitingPhase 1/2University Hospital TuebingenNCT05366218Written as Tafasitamab
- Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabRecruitingPhase 2Incyte CorporationNCT06465433Written as Tafasitamab
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingPhase 1OHSU Knight Cancer InstituteNCT05943496Written as Tafasitamab
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingPhase 2University of CologneNCT05583071Written as Tafasitamab
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05910801Written as Tafasitamab
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT06521255Written as Tafasitamab
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingPhase 2Beijing InnoCare Pharma Tech Co., Ltd.NCT05552937Written as Tafasitamab and Lenalidomide
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingPhase 3Incyte CorporationNCT05429268Written as Tafasitamab
See all 43 studies that test tafasitamab →
Given in every arm · 9 — tafasitamab is usual care beside what is tested
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434363Written as Tafasitamab
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Tafasitamab
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingPhase 1/2Incyte Biosciences Japan GKNCT04661007Written as tafasitamab
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as Tafasitamab
- Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLLCompletedPhase 2Ohio State University Comprehensive Cancer CenterNCT02005289Written as MOR00208
- Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationSuspendedPhase 1City of Hope Medical CenterNCT05993611Written as Tafasitamab
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Tafasitamab
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)TerminatedPhase 2Xencor, Inc.NCT05328102Written as Tafasitamab
- Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedPhase 2MorphoSys AGNCT02639910Written as Tafasitamab
Codes
What other systems call tafasitamab · ClinicalTrials.gg INT000583
- MeSH (NLM) C000613469tafasitamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QQA9MLH692TAFASITAMABConfirmed FDA, NLM, Wikidata
- RxNorm 2387211One source FDA
- Wikidata Q98078915tafasitamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95768TafasitamabOne source FDA
- DrugBank DB15044One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613469 | tafasitamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QQA9MLH692 | TAFASITAMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2387211 | — | One source FDA |
| Wikidata | Q98078915 | tafasitamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95768 | Tafasitamab | One source FDA |
| DrugBank | DB15044 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.